Haematological malignancies
Epizyme Inc. is active in clinical research for relapsed/refractory follicular lymphoma, with studies centered on treatment approaches for patients whose disease has returned or no longer responds to prior therapy. The sponsor’s research includes combinations with lenalidomide and rituximab in adult patients.
- Follicular lymphoma
- Relapsed/refractory disease
- Combination therapy
Clinical interest also extends to ongoing evaluation of long-term safety in patients remaining on tazemetostat-based treatment.
Solid tumours
The sponsor funds research in advanced solid tumours, including patients with significant disease burden and complex treatment needs. These studies broaden the therapeutic scope of its oncology programme beyond lymphoma.
- Advanced solid tumours
- Oncology
- Tumour treatment
This area includes patients with diverse malignancies receiving ongoing oral targeted therapy support.
Hematological malignancies
Epizyme Inc. also investigates hematological malignancies more broadly, reflecting interest in blood cancers beyond a single diagnosis. The clinical programme includes patients with malignancies requiring continued disease control and treatment monitoring.
- Blood cancers
- Malignancy management
- Targeted oncology
Research in this area is linked to treatment use in patients with varying disease histories and prior therapy exposure.
Hepatic impairment
Another focus is the use of tazemetostat in patients with moderate or severe hepatic impairment, alongside those with advanced cancers. This supports clinical assessment in populations with reduced liver function and oncology comorbidity.
- Hepatic impairment
- Liver function
- Special populations
These studies address treatment considerations where organ function is a key factor in cancer care.
Oncology maintenance and rollover treatment
Epizyme Inc. supports research involving patients continuing tazemetostat from antecedent studies, indicating interest in treatment continuity and extended clinical follow-up. This area includes patients transitioning between related oncology studies.
- Tazemetostat
- Long-term treatment
- Study rollover
The sponsor’s portfolio therefore spans active disease treatment, continued therapy, and safety monitoring across oncology settings.
